The FDA has agreed that Spectrum Pharma can remove from the labelling of Zevalin (ibritumomab tiuxetan) a requirement for a...
Baxalta Inc announced the publication of pivotal phase III data for BAX 111 (recombinant von Willebrand Factor) in Blood, the...
Mixed results from HEALOS Phase III trial of AM 111 to treat profound sudden deafness
Baxter International Inc. announced topline results from a Phase III clinical trial evaluating the safety, efficacy and pharmacokinetics (PK) of...
Baxter International Inc. announced initiation of a Phase III clinical trial to evaluate the safety and effectiveness of BAX 111,...
This medicinal product is for diagnostic use only. After radiolabelling with gallium ( 68 Ga) chloride solution, the solution of gallium ( 68 Ga) edotreotide obtained is indicated for positron emission tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastro-enteropancreatic neuroendocrine tumours (GEP-NET) for localising primary tumours and their metastases.
VBL Therapeutics announced the online publication of positive results of the pre-specified interim analysis of the OVAL study, a Phase III registration enabling study of VB 111 (ofranergene obadenovec) in recurrent platinum-resistant ovarian cancer.
VBL Therapeutics reported top-line results from its pivotal Phase III GLOBE study in patients with recurrent glioblastoma (rGBM) which was...
Baxter International Inc. announced that the company has submitted a biologics license application (BLA) to the FDA for the approval...
Auris Medical Holding AG announced that it has completed patient enrollment in the Phase III HEALOS clinical trial of AM...